Imugene licenses potential first-to-market allogeneic CAR T for blood cancers
Imugene's azercabtagene zarpreleucel (azer-cel) allo-CAR T cell therapy has shown a 58% ORR and 41% CR rate across all doses.
Imugene's azercabtagene zarpreleucel (azer-cel) allo-CAR T cell therapy has shown a 58% ORR and 41% CR rate across all doses.
What's Your Reaction?
